SURGE Therapeutics (SURGE), a clinical-stage oncology company pioneering intraoperative immunotherapy, today announced the final patient has been dosed in its Phase 1 clinical trial of SRG-514, an ...

Evommune surged 70% after EVO301's Phase 2a data showed rapid, significant EASI reductions in moderate-to-severe atopic dermatitis. EVO301's multi-pathway IL-18 inhibition offers broad potential, but ...

Single women are driving a surge in homeownership, outpacing single men by 7% in purchases, showcasing their growing financial confidence and investment savvy. MAPLE ...

The Hollywood Reporter's executive editor of awards coverage dissects Thursday morning's announcement. By Scott Feinberg Executive Editor of Awards 1) As Netflix and Paramount fight for Warner Bros., ...

The memory giant projected an operating profit of 20 trillion won for the final quarter of 2025. That came as memory prices surged an estimated 40%-50% in the quarter of 2025. Samsung still lags SK ...

A pair of phase 3 psoriasis studies of Alumis’ TYK2 inhibitor have hit their primary endpoints, setting the biotech up to file for approval of a potential challenger to Bristol Myers Squibb’s Sotyktu.

Trump Media & Technology Group’s (NASDAQ: DJT) stock provided an astonishing surprise to the market, jumping approximately 42% in just one session and marking one of its most dramatic one-day ...

(RTTNews) - Exicure, Inc. (XCUR) skyrocketed 41.37%, adding $2.18 to trade at $7.45, after the company announced positive topline results from its Phase 2 study of burixafor in multiple myeloma. The ...